On Friday, ImmunityBio Inc (NASDAQ: IBRX) opened higher 1.29% from the last session, before settling in for the closing price of $5.03. Price fluctuations for IBRX have ranged from $3.10 to $10.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 195.19% over the past five years. Company’s average yearly earnings per share was noted 27.54% at the time writing. With a float of $159.58 million, this company’s outstanding shares have now reached $670.87 million.
Let’s look at the performance matrix of the company that is accounted for 628 employees. In terms of profitability, gross margin is -26.45%, operating margin of -4900.23%, and the pretax margin is -8018.24%.
ImmunityBio Inc (IBRX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ImmunityBio Inc is 77.10%, while institutional ownership is 9.88%.
ImmunityBio Inc (IBRX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 27.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.70% during the next five years compared to 1.17% growth over the previous five years of trading.
ImmunityBio Inc (NASDAQ: IBRX) Trading Performance Indicators
Check out the current performance indicators for ImmunityBio Inc (IBRX). In the past quarter, the stock posted a quick ratio of 2.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 491.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.89, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.67 in one year’s time.
Technical Analysis of ImmunityBio Inc (IBRX)
ImmunityBio Inc (NASDAQ: IBRX) saw its 5-day average volume 4.14 million, a negative change from its year-to-date volume of 4.97 million. As of the previous 9 days, the stock’s Stochastic %D was 46.25%. Additionally, its Average True Range was 0.50.
During the past 100 days, ImmunityBio Inc’s (IBRX) raw stochastic average was set at 44.47%, which indicates a significant decrease from 46.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.11% in the past 14 days, which was higher than the 90.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.27, while its 200-day Moving Average is $5.28. Nevertheless, the first resistance level for the watch stands at $5.21 in the near term. At $5.32, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.49. If the price goes on to break the first support level at $4.93, it is likely to go to the next support level at $4.77. The third support level lies at $4.66 if the price breaches the second support level.
ImmunityBio Inc (NASDAQ: IBRX) Key Stats
There are currently 696,831K shares outstanding in the company with a market cap of 3.60 billion. Presently, the company’s annual sales total 620 K according to its annual income of -583,200 K. Last quarter, the company’s sales amounted to 6,110 K and its income totaled -85,730 K.
